Coreg combines non-selective beta-blockade with alpha-1 antagonism, offering both heart-rate reduction and vasodilation. This dual action can provide greater blood-pressure reduction compared with cardio-selective beta-blockers, which lack the alpha-blocking effect.
Yes, Coreg is often prescribed twice daily, typically morning and evening, to maintain stable plasma levels over 24 hours. Taking the evening dose at the same time each night helps avoid missed doses.
Blood-pressure effects may be noticeable within 1-2 weeks, but the full antihypertensive benefit often requires several weeks of gradual dose titration.
Carvedilol’s non-selective beta-blockade can provoke bronchospasm in asthma or severe COPD. It should be avoided in uncontrolled asthma, and if necessary, used only under close medical supervision with the lowest effective dose.
Peripheral edema can be a sign of fluid retention, especially in heart-failure patients. Report the swelling to your prescriber promptly; dosage adjustment or adding a diuretic may be required.
Some decongestants (e.g., pseudoephedrine) have sympathomimetic activity that may counteract beta-blockade, potentially raising blood pressure. Consult a pharmacist before combining Coreg with OTC cold remedies.
Carvedilol does not have a direct effect on lipid metabolism, so it neither raises nor lowers cholesterol. However, improved heart-failure control can indirectly support a healthier lipid profile.
No specific diet is required, but a balanced, low-sodium diet can enhance blood-pressure control. Avoid excessive alcohol, as it may increase dizziness and hypotension.
Carvedilol is classified as pregnancy category D in the UK, indicating evidence of fetal risk. It should be discontinued before conception or switched to a safer alternative under obstetric guidance.
Carvedilol is not a prohibited substance under the World Anti-Doping Agency (WADA) code, but athletes should disclose all prescribed medications to their sport’s medical team to avoid inadvertent violations.
Coreg is a brand-name medication that contains carvedilol as its active ingredient. Carvedilol belongs to the Heart & Blood Pressure therapeutic class and is formulated as a pill. The available strengths in the United Kingdom are 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg. Coreg is a prescription-only medicine (Rx) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Carvedilol is a non-selective beta-blocker with alpha-1 blocking activity. By blocking β₁ receptors in the heart, it reduces heart rate and contractile force, lowering cardiac output. Simultaneously, α₁-blockade causes vasodilation of peripheral blood vessels, decreasing systemic vascular resistance. The combined effect lowers both blood pressure and myocardial oxygen demand, which is useful in hypertension and chronic heart failure. Carvedilol is absorbed rapidly after oral administration, with an onset of action within 1-2 hours; peak plasma concentrations occur around 2-4 hours, and the drug’s half-life is approximately 7-10 hours, allowing twice-daily dosing.
Coreg is approved in the UK for the following indications:
These approvals are based on robust clinical trials reviewed by the European Medicines Agency (EMA) and adopted by the MHRA. Coreg is intended for adult patients; paediatric use is not approved.
These effects are usually mild and may improve as the body adapts to the medication.
Prompt medical attention is required if any of these occur.
Administration tips: Swallow the pill whole with a full glass of water. Do not crush or chew. Store at room temperature, protected from moisture and heat.
If a dose is missed: Take it as soon as remembered unless it is almost time for the next dose; do not double the dose.
Overdose: Symptoms may include severe bradycardia, hypotension, and respiratory depression. Seek emergency medical care; treatment is supportive, and atropine may be used for symptomatic bradycardia.
Discontinuation: Sudden withdrawal can precipitate angina or myocardial infarction. Taper the dose gradually under medical supervision, especially in heart-failure patients.
Regular follow-up with a healthcare professional is essential to ensure optimal dosing and to detect adverse effects early.
This article provides educational information about Coreg and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
